Kornimate/medical-research-clean huggingface dataset:
aromatherapy with lavender as anxiolysis prior to cataracts surgery

Conditions: Aromatherapy; Anxiety

Summary: the purpose of this study is to assess the validity of lavender aromatherapy as a method of anxiolysis prior to a cataract surgery, and to see if this effect will extend intraoperatively to minimize patients' intraoperative medication requirements. the study team plans on enrolling 186 participants. the investigator team hypothesizes that: 1. participants will have a lower anxiety score after the intervention 2. participants will require less intraoperative sedation medication compared to participants that did not have the lavender intervention. 3. a decrease in intraoperative medication requirements will lead to a faster discharge time

all participants will arrive at the hutchinson campus on the morning of surgery. after nursing intake, participants will be consented into the study. vital signs will be recorded, as is part of the typical nursing intake. after the consent is completed, participants will receive the visual analogue scale (vas) anxiety questionnaire. participants that are part of the experimental group will then have the bioesse lavender patch placed on the chest, according to manufacturer recommendations. after the lavender has been in place for 5 minutes, the same vas anxiety questionnaire will be provided for completion. the control subjects will only receive the initial vas questionnaire. after this, all participants will receive the same premedication, including fentanyl and midazolam prior to cataract surgery, and will have monitored anesthesia care (mac) during the case. in the second phase of the study, chart review will be completed to monitor the patients' intraoperative sedation requirements . additionally, demographic data will be taken at this time, including age, race, and sex.

Eligibility criteria:
inclusion criteria: * over the age of 18 * asa (american society of anesthesiology) score \<=3 * patients must be able to consent to participating in the study exclusion criteria: * asa score \>4 * patients with a psychiatric diagnosis or who are on psychiatric medication * patients with a history of asthma * patients with an allergy to lavender * patients under an anesthetic plan that has been switched from local anesthesia with sedation to general anesthesia * vas score \> 60 pre-operatively (high anxiety score)
mri imaging of labeled human islets transplanted into the liver

Conditions: Type 1 Diabetes Mellitus

Summary: the purpose of the study is to determine whether human islets labeled by iron contrast agents could be imaged using magnetic resonance after transplantation into the liver of type 1 diabetic recipients.

islet transplantation represents approved therapeutic approach in selected type 1 diabetic recipients with syndrome of hypoglycaemia unawareness. existing imaging methods are not sufficient to provide adequate information about amount and fate of islets transplanted into the liver. labeling of islets with superparamagnetic contrast agent ferucarbotran significantly shortens t2 relaxing time and therefore increase the contrast between islets and liver tissue in magnetic resonance imaging. in consequence, islets transplanted into liver could be easily detectable like hypotensive areas dispersed throughout the liver. mri examination will be done on 1, 2, 4 weeks and 3, 6 and 12 months.

Eligibility criteria:
inclusion criteria: * type 1 diabetes mellitus * normal renal parameters * hypoglycaemia unawareness or rapid progression of diabetic retinopathy or neuropathy exclusion criteria: * acute and chronic liver disease * malignancy * acute infection * serious cardiovascular disease * coagulopathy * portal hypertension * presence of metal protesis, cardio-stimulators, or other metal material in the body

Keywords: islet transplantation magnetic resonance type 1 dm
formulation of compensation based intervention

Conditions: Stroke

Summary: the primary aim of this study was to pilot cbpst as a novel intervention method. by applying it to a pilot group, the research sought to contribute to the existing literature by offering a compensation-based rehabilitation approach

the study was designed as prospective and a randomized controlled pilot study. a simple randomization method was employed to randomly assign individuals to two groups (intervention and control groups). a simple randomization method was employed, whereby the intervention and control group papers were selected from a closed envelope. following the initial evaluation of each participant, one of the papers bearing the designation "intervention" or "control" was selected at random. this decision determined whether the individual would be included in the intervention or control group. the study was conducted in the occupational therapy department of the physical therapy and rehabilitation clinic of etlik city hospital. the study was approved by the ethics committee of etlik city hospital and was assigned the code aeşh-ek-2025-025. following approval from the ethics committee, the compensation-based problem solving training (cbpst) was developed. the training program was developed in accordance with the tenets of the occupational adaptation model. all subsequent steps were conducted in accordance with the aforementioned model. the adaptive response, as outlined in the model, encompasses the occupational adaptation that is anticipated to occur at the conclusion of the training program. the therapy was then trialled with a pilot group of five individuals, with the aim of refining the content. subsequently, the final iteration of the training program was established. all individuals included in the study signed a consent form indicating their willingness to participate. this was completed at the outset of the study. all individuals were provided with a standard rehabilitation program comprising five days a week (40 minutes) of routine therapy. in addition to this, the intervention group received cbpst in the form of five days a week (20 minutes) sessions. the evaluations completed at the beginning of the training were repeated one month later.

Eligibility criteria:
inclusion criteria: * a diagnosis of ischemic stroke due to a middle cerebral lesion, * age between 18 and 64 years, * a score of 24 or above on the standardized mini-mental state examination -- * willingness to participate in the study. exclusion criteria: * stroke onset between 3 and 12 months prior to the study, * presence of aphasia (speech impairment) * diagnosis of another chronic condition that could affect study outcomes

Keywords: activities of daily living stroke compensatory problem solving participation
recombinant human granulocyte monocyte - colony stimulating factor (gm csf) for prevention of pneumonia in patients with cirrhosis

Conditions: Cirrhosis

Summary: informed consent obtained from the patient or the patient's legal surrogate. the window for randomization and initiation of study drug infusion is 2 days from day of admission. all further time points are relative to the day of randomization. patients will be randomized (1:1) to receive either recombinant human gm-csf or placebo. using randomized block design of 10 each generated by computer and provided in sequential, sealed, opaque envelopes. subjects will be stratified based on child status. patients who fulfil the inclusion criteria will receive either slow iv infusion of gm csf (sargamostatim-250mcg/m2) over 4 hour and inhalation of same dose by micronebulizer for 7 days or placebo(saline infusion and saline nebulization). standard medical care will be given in both limbs.


Eligibility criteria:
inclusion criteria: * patient with cirrhosis admitted to icu-hdu without pneumonia at admission * 18-70 years of age * child b/ c exclusion criteria: * patient having pneumonia * if there is evidence of preexisting chronic respiratory failure * if the patients is neutropenic (absolute neutrophil count \<1000 cells/mm3 * if there was a history of hematological malignancy or bone marrow transplantation * person having hcc * acute liver failure * pregnancy * hiv
a phase ii study of pemetrexed and carboplatin in the treatment of esophageal cancer

Conditions: Esophageal Neoplasms

Summary: this is a study of an investigational agent, pemetrexed, in combination with a standard chemotherapy drug, carboplatin, for treatment of patients with metastatic esophageal cancer.


Eligibility criteria:
inclusion criteria: * patients must have a histologically or cytologically proven metastatic or recurrent esophageal cancer. both adenocarcinoma and squamous carcinoma are eligible for the study. patients with small cell carcinoma or sarcoma of the esophagus are not eligible for the study. * patients may have had no prior chemotherapy treatment for metastatic esophageal cancer. patients may have had chemotherapy with 5-fu combined with definitive radiotherapy for curative intent in the adjuvant, neoadjuvant, or definite setting for locally advanced esophageal cancer, if no less than one year prior to trial enrollment. patients may not have received pemetrexed in the past. * patients who have had radiotherapy for esophageal cancer must have completed radiotherapy at least four weeks prior to entry in the study. * patients need to have measurable disease. * lesions that are not considered measurable include the following: * bone lesions * brain metastases or leptomeningeal disease * ascites * pleural/pericardial effusion * abdominal masses that are not confirmed and followed by imaging techniques * cystic lesions * tumor lesions situated in a previously irradiated area * ecog) performance status of 0-2. * life expectancy of \>=12 weeks. * patients must have adequate bone marrow function defined as: white blood cells (wbc) \>= 3000/mm\^3, absolute neutrophil count (anc) \>= 1,500/mm\^3, hemoglobin \>= 9.0 g/dl, and platelet count \>= 100,000/mm\^3. * patients must have adequate liver function defined as: bilirubin \<= 1.5 x institutional normal and alt/ast \< 3 x institutional normal. * patients must have adequate renal function defined as: serum creatinine \ = 45 ml/min. * radiation therapy for brain metastases should be completed at least four weeks prior to enrollment to this protocol. * patients must have recovered from uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or uncontrolled symptomatic cardiac arrhythmia. * patients must be able to be compliant with premedications of dexamethasone, folic acid, and vitamin b12. * for all sexually active women of child-bearing age, the use of adequate contraception (hormonal or barrier method of birth control) will be required prior to study entry and for the duration of study participation. * age \>= 18 years. * written consent. * ibuprofen (400 mg qid) can be administered with alimta in patients with normal renal function (creatinine clearance \> 80 ml/min exclusion criteria: * patients with third-space fluid (pleural effusions, ascites, etc.) uncontrolled by drainage. * pregnant or nursing females * patients who have had pre-existing neuropathy greater than or equal to grade 2. * patients with known active cns metastases.
observatory on emergency care for acute coronary syndrome in grand est of france

Conditions: Acute Coronary Syndrome

Summary: the purpose is to build up a data observatory of individuals with thoracic pain evoking acute coronary syndrome (acs). the aim is the characterization of this population of patients consulting at emergency department, the evaluation of therapeutic strategies with regard to guidelines and the becoming of patients including severe complications and mortality.


Eligibility criteria:
inclusion criteria: * resident in grand est of france (lorraine, champagne ardenne) under medical care at the emergency room or outside of hospital or in cardiology: * outside of hospital: for thoracic or epigastric pain with suspicion of acs emergency: for thoracic pain for which the doctor will prescribe troponin or troponin kinetics * affiliation to social security exclusion criteria: * patient affected by acs with st segment elevation * patient with traumatic thoracic pain * patient with thoracic pain of parietal origin * patient with consciousness troubles
diagnostic performance of [11c]choline pet/ct in the preoperative assessment of primary hyperparathyroidism

Conditions: Primary Hyperparathyroidism

Summary: primary hyperparathyroidism (hpt) ranks as the third most common endocrine disorder, characterized by excessive secretion of parathormone (pth), a hormone crucial for regulating calcium and phosphorus metabolism within the body. the only cure for hpt is surgically removing the hyperfunctioning parathyroid tissue, both in symptomatic and asymptomatic settings. with the advance of preoperative medical imaging techniques, a paradigm shift has taken place in the surgical approach of this condition, evolving from an inpatient bilateral cervical exploration to an outpatient minimally invasive procedure, which has proved to be superior in outcome. due to the small size of the glands, preoperative visualisation and localisation are mandatory for the surgeon. several imaging methods have been researched for identifying hyperfunctioning parathyroid glands, including morphological, functional and hybrid techniques, with no clear agreement on the optimal imaging approach.the preoperative localization modalities available are ultrasonography; parathyroid scintigraphy using technetium \[99mtc\]tc sestamibi (mibi), multiphase multidetector 4d computed tomography (4dct); magnetic resonance imaging; and recently, positron-emission tomography/computed tomography (pet/ct) using 11c- and 18f-labelled radiotracers. while ultrasound and \[99mtc\]tc-mibi scintigraphy have been long used to diagnose and monitor patients with hpt, they can lead to numerous false negative results and therefore require additional examinations.choline pet/ct is steadily replacing conventional imaging in many centres, allowing for the localization of adenomas in three quarter of patients with negative previous imaging examinations, but is still considered a relatively new method. \[11c\]c-choline (\[11c\]ch) pet/ct is gradually gaining ground as a reliable method of localising hpt preoperatively, due to its fast uptake in hyperfunctioning parathyroid tissue, shorter acquisition time and lower radiation exposure compared to other nuclear medicine investigations and conventional methods. \[11c\]ch pet/ct has been suggested to be superior in diagnostic performances, compared to other imaging methods, reaching sensitivities up to 98.9%.the aim of our retrospective, single centre study is to evaluate the diagnostic performances and the inter-observer agreement of \[11c\]ch pet/ct for the preoperative detection of parathyroid adenomas in patients with suspected primary hpt.


Eligibility criteria:
inclusion criteria: * patients with biochemically proven hpt, either through elevated serum levels of pth or normal pth despite hypercalcemia; * age ≥ 18 years old; * \[11c\]ch pet/ct for hpt before eventual surgery. exclusion criteria: * pregnancy or breast-feeding.
a case control study to investigate the possible association between atrial fibrillation and endothelium dysfunction by using flow-mediated vasodilation method

Conditions: Atrial Fibrillation; Endothelial Function

Summary: endothelial function is closely related to the hemostasis , vascular tone, and organ perfusion in cardiovascular system, and its dysfunction would cause overactivation of the coagulative system to induce thrombus formation. so we study the relationship between the endothelial function and atrial fibrillation.


Eligibility criteria:
inclusion criteria: * lone af patients and normal controls exclusion criteria: * dm, hypertension, hyperlipidemia, smoking, pregnancy,
study of bladder-sphincter symptoms in functional neurological disorders

Conditions: Urinary Bladder Sphincter Disorder

Summary: a significant proportion of patients with functional neurological disorders (fnd) report urinary, anorectal or genitosexual disorders. however, until now, no study has focused on bladder-sphincter disorders in patients with fnd. the symptoms of this pathology are, therefore, not precisely characterized. thus, the objective of this research is to specify if urinary, anorectal or sexual disorders can be observed in patients suffering from functional neurological disorders and to better describe them in order to propose better therapeutic options.

in this clinical study the investigators want to prospectively include all patients presenting to a neurology consultation or day hospital for management of a motor or sensory fnd.the patients will first be evaluated for their sphincter functions by self questionnaires. for those where a vesico-sphincter complaint is demonstrated, a neuro-urological consultation will be proposed. a follow-up will then be done, if necessary, in neurology and neuro-urology.

Eligibility criteria:
inclusion criteria: * patient over 18 years of age * diagnosis of functional neurological disorders according to dsm 5 criteria * no neurological comorbidity that could account for the sphincter disorders * normal cerebral and spinal cord magnetic resonance imaging. * patient affiliated to a french social security system * patient informed and not objecting to participate in the study non inclusion criteria : * presence of neurological comorbidity that can account for sphincter disorders (e.g. multiple sclerosis, chronic neuropathy, etc.) * pregnancy in progress * candidate for surgery or locoregional treatment * patient subject to legal protection measures. * patient under state medical assistance
efficiency and quality in post-surgical pain therapy after discharge

Conditions: Opioid Use; Opioid Dependence; Opioid Misuse; Post-Surgical Complication

Summary: following inpatient surgery, more than 80% of patients are prescribed opioids for use after discharge, yet up to 90% of patients report leftover opioids, and only 16% maximize non-opioid therapy. the proposed research seeks to test a provider-facing decision support tool and a patient-facing smartphone app to reduce the amounts of opioids prescribed and taken following discharge, while ensuring effective treatment of pain after surgery.

prior to discharge from the hospital, patients will be approached regarding interest in the study with an introductory letter that describes the content and purpose of the study. following informed consent, patients will be randomized to receive the consumer health informatics app (ucontrolpain) versus provision of an app with only data collection function (no educational components). randomization will be implemented via redcap by the study coordinators. further, information on which type of app was installed will not be shared with providers or patients.

Eligibility criteria:
inclusion criteria: 1. \>19-89 years old 2. access to a smartphone (ios or android) 3. inpatient surgery requiring at least over-night hospitalization with anticipated discharge to home exclusion criteria: 1. patients re-hospitalized within 30 days of previous hospitalization 2. pregnant patients 3. patients not able to read the english language 4. patients discharged to a post-acute care facility 5. patients with contraindications to opioids, acetaminophen, or nsaids 6. patients meeting the ahrq definition of long-term opioid therapy (opioid use on most days \>3 months) prior to surgery.
safety & immunogenicity study of meningococcal vaccine gsk134612 given with priorix-tetra™ to 12-23 month-old children

Conditions: Infections, Meningococcal

Summary: the purpose of this study is to demonstrate, in 12-23 month old children, the non-inferiority of the meningococcal vaccine 134612 given with priorix-tetra. the protocol posting has been updated in order to comply with the fda amendment act, sep 2007.

open multicentre study with 4 treatment groups. two groups will receive the 134612 vaccine with priorix-tetra either at the same or different visits followed by a second priorix-tetra vaccination at 84 days. two control groups will receive priorix-tetra and meningitec at different visits followed by a second priorix-tetra vaccination at 84 days. for all subjects, two blood samples will be taken: prior to and 42 days after the first vaccination. in a subset (30% of subjects in groups a en c) from selected study centres: additional sample 42 days after second priorix-tetra dose.

Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol. * a male or female between, and including, 12 and 23 months of age at the time of the vaccination. * written informed consent obtained from the parent or guardian of the subject. * free of obvious health problems as established by medical history and clinical examination before entering into the study. * previously completed routine childhood vaccinations to the best of parents' or legal guardians' knowledge. exclusion criteria: * use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose. * planned administration/ administration of a vaccine not foreseen by the study protocol within one month before and 42 days after the first dose of vaccine(s). * previous vaccination with meningococcal vaccine of serogroup a, c w and/or y. * history of meningococcal disease. * previous vaccination against measles, mumps, rubella, and/or varicella. * history of measles, mumps, rubella and/or varicella. * known exposure to measles, mumps, rubella, varicella or zoster within 30 days prior to vaccination. * any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (hiv) infection, based on medical history and physical examination. * history of allergic disease or reactions likely to be exacerbated by any component of the vaccine, including neomycin. * major congenital defects or serious chronic illness. * acute disease at the time of enrolment. * administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.

Keywords: mmrv vaccine co-administration immunogenicity meningococcal vaccine conjugate vaccine
effect of vojta therapy on upper extremity function of children with cerebral palsy

Conditions: Cerebral Palsy; Upper Extremity; Vojta Therapy

Summary: the goal of this pilot study is to study the effect of vojta therpy on upper extremity function in children with cerebral palsy. the main questions are: * to study the effect of vojta therapy on upper extremity function in children with cerebral palsy in terms of range of motion and function * to study the effect of vojta therapy on upper extremity function in children with cerebral palsy in terms of motion analysis while perform function

vojta therapy is an old treatment method which was discovered by professor vaclav vojta, a neurologist and pediatrician. it has been used to treat children with impair motor function in thailand since 2011. vojta therapy encourage the movement of children via positioning and stimulate the specified zone.

Eligibility criteria:
inclusion criteria: * spastic diplegia (macs ii-iii) * can pick box and block test at least 1 block * has good trunk stability while sitting * can follow command * participant and guardian consent to the study exclusion criteria: * no vojta therapy in last 2 months * no history of anti-spastic injection in last 6 months * do not receive prednisolone nor adrenocorticotropic hormone (acth) * cannot control seizure * got the specific disease such as osteogenesis imperecta, cardiac disease * participant and guardians do not consent to the study.